Jonathan Cooper

Professor of Pediatrics, Professor of Genetics, Professor of Neurology

    • 6856 Citations
    1987 …2020

    Research output per year

    If you made any changes in Pure these will be visible here soon.

    Personal profile

    Research interests

    1. The early stages of my career were spent investigating the influence of target-derived neurotrophins upon neurons of the cholinergic basal forebrain and how this altered during development, different stages of maturation and in aging. This revealed significant new information about how in these different contexts neurotrophins such as NGF, BDNT and NT-3 variably influenced neuron survival, or phenotype. This was a prelude to investigating the same issues in a mouse model of Down syndrome, revealing that the failure of retrograde transport of NGF contributed to the apparent loss of cholinergic neurons, but that these ‘phenotypically silent’ neurons could be rescued by administration of NGF. 2. The first phase of my work on the neuronal ceroid lipofuscinoses (NCLs or Batten disease) involved answering fundamental questions about how the brain is affected and the staging of pathology in these disorders. This work for the first time defined which neuron populations are affected, revealing that it is remarkably selective in the early stages of pathogenesis. The first vulnerable neuron population to be identified was GABAergic interneurons, followed by the staging of neuron loss within the thalamocortical system, which revealed the thalamus as an unexpected pathological target in these disorders. We also demonstrated the selective effects upon populations of cerebellar neurons, and have continued this work to reveal an unexpectedly severe pathology in the brainstem and spinal cord. More recently we have revealed the involvement of the peripheral, autonomic and enteric nervous systems and are investigating their contribution to disease outcome. 3. Following these discoveries we have been working to understand the selective nature of neuron loss in the NCLs and what might influence this. By comparing the relative timing and distribution of neuron loss to storage material accumulation, astrocytosis and microglial activation we have learnt fundamental lessons about the staging of NCL pathogenesis and how it differs between disease subtypes. There appears to be no direct correlation between neuron loss and storage material accumulation. Instead there is a much closer correlation between glial activation and neuron loss, with either astrocytosis or microglial activation consistently preceding neuron loss, leading us to investigate the nature of neuron:glial interactions and how they may be compromised. Our work has provided evidence that glia are dysfunctional and may directly compromise neuron health, resulting in neuron loss. These studies have highlighted that while different forms of NCL share broad pathological similarities they differ fundamentally in many respects. 4. We have been using the disease landmarks gained through these neuropathological studies to test the efficacy of a variety of pre-clinical experimental therapies. Indeed, we are increasingly asked to undertake this work by a wide-network of academic and industrial collaborators around the world. As such, we have played key roles in studies of gene therapy, neural stem cell transplantation, enzyme replacement, and a variety of small molecule approaches. These include glutamate receptor antagonists, immunosuppressants, and antiinflammatory compounds, with an increasing focus on trying different combinations of experimental therapies in order to potential increase their efficacy. Most recently we identified that treating the brain and spinal cord has a powerful synergistic effect in a mouse model of Cln1 disease. This work has led to several clinical trials including that of mycophenolate mofetil in Cln3 disease, neural stem cell transplants in Cln1 and Cln2 disease, and a successful enzyme eplacement trial in Cln2 disease, which has just been approved by the FDA and EMA as the first ever treatment for CLN2 disease.

    Fingerprint Dive into the research topics where Jonathan Cooper is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

    • 4 Similar Profiles

    Network Recent external collaboration on country level. Dive into details by clicking on the dots.

    Research Output

    Comparative proteomic profiling reveals mechanisms for early spinal cord vulnerability in CLN1 disease

    Nelvagal, H. R., Hurtado, M. L., Eaton, S. L., Kline, R. A., Lamont, D. J., Sands, M. S., Wishart, T. M. & Cooper, J. D., Dec 1 2020, In : Scientific reports. 10, 1, 15157.

    Research output: Contribution to journalArticle

    Open Access
  • Future perspectives: What lies ahead for Neuronal Ceroid Lipofuscinosis research?

    Cooper, J. D. & Mole, S. E., Jan 1 2020, (Accepted/In press) In : Biochimica et Biophysica Acta - Molecular Basis of Disease. 165681.

    Research output: Contribution to journalReview article

  • 1 Scopus citations

    Generation of light-producing somatic-transgenic mice using adeno-associated virus vectors

    Karda, R., Rahim, A. A., Wong, A. M. S., Suff, N., Diaz, J. A., Perocheau, D. P., Tijani, M., Ng, J., Baruteau, J., Martin, N. P., Hughes, M., Delhove, J. M. K. M., Counsell, J. R., Cooper, J. D., Henckaerts, E., Mckay, T. R., Buckley, S. M. K. & Waddington, S. N., Dec 1 2020, In : Scientific reports. 10, 1, 2121.

    Research output: Contribution to journalArticle

    Open Access
  • Myelin and Lipid Composition of the Corpus Callosum in Mucopolysaccharidosis Type I Mice

    Le, S. Q., Nestrasil, I., Kan, S. H., Egeland, M., Cooper, J. D., Elashoff, D., Guo, R., Tolar, J., Yee, J. K. & Dickson, P. I., 2020, (Accepted/In press) In : Lipids.

    Research output: Contribution to journalArticle

  • Pathomechanisms in the neuronal ceroid lipofuscinoses

    Nelvagal, H. R., Lange, J., Takahashi, K., Tarczyluk-Wells, M. A. & Cooper, J. D., Sep 1 2020, In : Biochimica et Biophysica Acta - Molecular Basis of Disease. 1866, 9, 165570.

    Research output: Contribution to journalArticle

  • 6 Scopus citations